跳至主要内容
临床试验/NCT03196882
NCT03196882已完成4 期

Effectiveness of Adaptation of the Dose of Iron Supplementation in Pregnancy on Maternal-child Health. Randomized Clinical Trial (ECLIPSES)

Victoria Arija Val2 个研究点 分布在 1 个国家目标入组 704 人开始时间: 2013年7月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
704
试验地点
2
主要终点
Anemia

研究概览

简要总结

Currently, there is no consensus regarding iron supplementation dose that is most beneficial for maternal and offspring health during gestation. This deficit, or excess, of iron prejudices the mother-child wellbeing. Therefore the hypotheses are that an iron supplementation adapted to values of hemoglobin at the start of the pregnancy will would be more effective in preventing iron deficiency, without increasing the risk of hemoconcentration by the end of pregnancy. This would be helped optimize mother-child health status.

The aims of the study are to determine the highest level of effectiveness of iron supplementation adapted to hemoglobin (Hb) levels in early pregnancy, which would be optimum for mother-child health.

To accomplish this objective a Randomized Clinical Trial (RCT) triple-blinded was designed. The study is structured as a RCT with 2 strata, depending on the Hb levels before week 12 of gestation.

Stratum 1: If Hb from 110 to 130 g/L, randomly assigned at week 12 to receive iron supplement of 40 or 80 mg/d.

Stratum 2: If Hb >130 g/L, randomly assigned at week 12 to receive iron supplement of 40 or 20 mg/d.

This study will be conducted in non-anemic pregnant women at early gestation stage, and their subsequent newborns. The data recollected to mothers will be: socio-economic data, clinical history, food item frequency, lifestyle and emotional state, and adherence to iron supplement prescription. In addition, biochemical measured will be Hemoglobin, serum ferritin, C reactive protein, cortisol, and alterations in the HFE gene (C282Y, H63D). In children, the data collected will be: ultrasound fetal biometry, anthropometric measurements, and temperament development

Should conclusive outcomes be reached, the study would indicate the optimal iron supplementation dose required to promote maternal and infant health. These results would contribute towards developing guidelines for good clinical practice.

详细描述

The study will be conducted in 2 Primary Care Centers (PCC) from Tarragona and Reus of the Catalunya Sexual and Reproductive Healthcare Service [Atención a la Salud Sexual y Reproductiva (ASSIR)] of the Catalan Institute of Health [Instituto Catalán de la Salud (ICS)]. The specialist health-care workers include gynecologists and midwives. The participating reproductive health-care services (RHS) provide cover for urban, suburban, and rural PCCs.

The clinical follow-up of the pregnancy in the PCC will be according to the program set by RHS. This includes a clinical visit at recruitment into the present study, a visit every trimester, and one at 40 days post-partum.

In the recruitment visit before week 12 of the pregnancy, the inclusion criteria will be assessed (except the Hb levels and the number of fetuses) as well as the exclusion criteria. Informed consent will be solicited. A clinical history will be recorded, which include date of birth, socioeconomic status, parity, date of last menstruation, corrected date of last menstruation, estimated date of partum, risk factors during pregnancy, pregnancy planning, previous use of contraceptives, clinical antecedents, surgery and personal obstetric data, toxic habits, blood pressure, height, weight of the mother (self-reported at the recruitment visit and measured objectively at each clinical follow-up visit). Similar data from the father will be solicited.

Moreover, a questionnaire regarding the ingestion of iron supplements, multi-vitamins, or other treatments and, if a smoker, the Fagerstrom test for tobacco dependency. A blood sample for standard biochemical analyses (including hemoglobin) will be sent for processing in the centralized laboratory.

At visit 1, around the 12th week of gestation, Hb levels will be evaluated as will be the number of fetuses (using echography) to confirm that the inclusion criteria are fulfilled. If fulfilled, the individuals will be retained in the study and, if not, will be transferred out of the study, and considered a screening failure. The remaining women will be assigned to Stratum 1 or Stratum 2 of the study and will be randomized with respect to iron supplement prescription. Clinical history will be taken, including the use of multi-vitamins and iron supplements and the questionnaires filled-in about food consumption, physical activity, anxiety status and tobacco dependency. ). A physical examination will be performed to measure weight and blood pressure. The ultrasound data on the fetus will be recorded to assess Crown Rump Length (CRL). A physical examination will be performed to measure weight and blood pressure. Venous blood will be taken for analyses, the results of which will be reviewed in the next clinical visit. The iron supplementation that will be needed at the next visit will be prepared for distribution. Adverse events occurring since the previous visit will be recorded.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

The study will be triple blind: the participant, the health-care professional, and the investigator-statistician. The treatment drug will be administered "blind" i.e. the doses are not identifiable since the packaging has the same format, presentation, and visual characteristics. For Stratum 1, the treatments will be designated as A or B, and for Stratum 2 they will be designated as C or D. The laboratory of MEIJI TEDEC FARMA, SA will be responsible for manufacturing, packaging and labeling the study medications. Only MEIJI TEDEC FARMA, SA and the Clinical Pharmacology Service of the Vall d'Hebron Hospital in Barcelona will know the distribution codes and the composition of each of the treatments.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Adult woman
  • ICS belonging to
  • Pregnant less than 12 weeks gestation,
  • To understand the Spanish or Catalan
  • Sign the informed consent
  • Without anemia (Hb <110 d / dL) in the pre-analytical at 12 weeks

排除标准

  • Multiple or risk pregnancy.
  • Taking iron supplements containing 10mg iron than in the previous three months
  • Pregnant women with hypersensitivity to the active substance, hypersensitivity to egg proteins or intolerant to fructose or galactose.
  • chronic or severe pre-existing disease that affects the nutritional development, such as cancer, diabetes mellitus and other metabolic diseases, malabsorptive diseases such as Crohn's disease, ulcerative colitis, gastro-duodenal ulcers, and liver diseases such as chronic hepatitis, liver cirrhosis and chronic pancreatitis.
  • Immunosuppression: chronic HIV infection, transplant, neutropenic, or patients receiving immunosuppressive therapy.

研究组 & 干预措施

Stratum 1: 40 mg/day of iron

Active Comparator

Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum

Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)

干预措施: 40mg/day of iron (Drug)

Stratum 1: 80 mg/day of iron

Experimental

Ferrimanitol ovoalbumin. 80mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum

Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)

干预措施: 80mg/day of iron (Drug)

stratum 2: 40 mg/day of iron

Active Comparator

Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum

Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)

干预措施: 40mg/day of iron (Drug)

stratum 2: 20 mg/day of iron

Experimental

Ferrimanitol ovoalbumin. 20mg of iron in a sachet (oral solution) by mouth, every 24 hours from 12th week of gestation to partum

Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)

干预措施: 20mg/day of iron (Drug)

结局指标

主要结局

Anemia

时间窗: at week 36 of gestation (3rd visit of study)

- Anemia is defined as Hb \<110 g/L in the 1st and 3rd trimester, Hb \<110 in 2nd trimester (Centers for Disease Control and Prevention, 1998).

ferropenic anemia

时间窗: at week 36 of gestation (3rd visit of study)

- Ferropenic anemia is defined as: Hb \< the normal limit, and serum ferritin (SF) \<15 μg/L (WHO, 2007)

Risk of hemoconcentration

时间窗: at week 36 of gestation (3rd visit of study)

- Hemoconcentration risk is defined as: Hb \>130 g/L in the 2nd and /or3rd trimester (Peña-Rosas y Viteri, 2009).

次要结局

  • C282Y polymorphisms of HFE gene(Blood analysis at 12 weeks of gestation.)
  • H63D polymorphisms of HFE gene(Blood analysis at 12 weeks of gestation.)
  • Neurorconductual development of newborn (Bayley Scales)(40days post-partum)
  • Anthropometric parameters of newborn.(At birth)

研究者

发起方
Victoria Arija Val
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Victoria Arija Val

Professor, MD

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

研究点 (2)

Loading locations...

相似试验